[Medium-term results of multisite biventricular stimulation in severe cardiac failure].
Since its introduction in cardiac failure in 1994, biventricular cardiac stimulation has been widely applied with many clinical trials and the development of new specific technology. The authors present the results observed in the first 125 consecutively implanted patients at the Rennes University Hospital. After a mean follow-up of 22 months, the mortality rate was 40%. The causes of death were sudden death in 42% of patients, progression of cardiac failure in 34% and non-cardiac in 24%. The functional benefits of biventricular cardiac stimulation were seen through significant improvement in HYHA Class, 3.3 +/- 0.5 before implantation to 2.3 +/- 0.8 at the end of follow-up, and by a significant increase of 40% of peak VO2 and of maximal duration of exercise. With the learning curve and development of new technology, the left ventricular catheterisation via a coronary sinus vein, increased from 56% to over 95% during the last two years with an acceptable rate of complications. These results, with the reserve of not being a controlled trial, show the feasibility, safety and efficacy of biventricular cardiac stimulation in terms of functional benefit. Clinical trials are currently underway to assess the impact of this method on morbi-mortality and to assess the concept in association with ventricular defibrillation.